Back Login to subscribe 🔔 Set Alert

SMMT Summit Therapeutics Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy	93.8%
	Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today	96.58%
	Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday	94.79%
	12 Health Care Stocks Moving In Wednesday's Pre-Market Session	95.6%
	Summit Therapeutics shares are trading higher after the company announced topline results from the randomized Phase III HARMONi-GI1 study met the key secondary endpoints of progression-free survival and objective response rate.	95.21%
	HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral	71.97%
	Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR	88.75%
	Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients	95.5%
	Summit Therapeutics shares are trading higher after the company announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $9.8 to $11.9.	94.26%
	Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9	94.05%

1
2
›